VolitionRX Limited Common Stock
Here’s whether VolitionRX Limited Common Stock (VNRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 40 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-9.10% over 10 days); weak 1-year return of -64.2%; 3-month momentum negative (-39.0%). Currently 81.0% off its 52-week high. Score: -5/7.
VNRX is trading below its 200-day MA ($0.41) — a key warning sign the longer-term trend is under pressure. An RSI of 40.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -64.2% compares to +35.1% for SPY (trailed the market by 99.3%). The current 81.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.